Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience.
Аннотация
BACKGROUND
Venous malformations (VMs) are slow-flow vascular anomalies frequently driven by somatic activating mutations in TEK/TIE2 receptor. Medical treatment options remain limited; while mTOR inhibition with sirolimus has shown moderate benefit, direct TIE2 inhibition has a strong biological rationale and emerging clinical evidence.
CASE PRESENTATION: We report a 51-year-old patient with a diffuse VM involving the right cervical region, thorax, and upper extremity, associated with a somatic mosaic TEK (L914F) variant. The disease was refractory to conventional therapies and complicated by chronic coagulopathy. Compassionate-use treatment with the selective TIE2 inhibitor rebastinib was initiated based on a previously reported patient. Over 3 years of follow-up, the patient experienced sustained clinical benefit with decreased pain and inflammation, partial volume reduction, functional improvement, and stabilization of coagulopathy with manageable toxicity. Unfortunately, the interruption in the production of the drug made it necessary to try other less specific alternatives like PI3K inhibitor alpelisib.
CONCLUSION
This second long-term clinical experience supports the sustained efficacy and safety of TIE2 inhibition in selected TEK-mutated VMs and highlights the therapeutic gap arised from drug discontinuation, underscoring the need for alternative targeted strategies and prospective evaluation.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.